RenovoRx (RNXT) Expected to Announce Earnings on Thursday

RenovoRx (NASDAQ:RNXT) is projected to announce its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $0.47 million for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:30 PM ET.

RenovoRx (NASDAQ:RNXT) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). The firm had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.42 million. RenovoRx had a negative net margin of 994.48% and a negative return on equity of 119.77%. During the same quarter last year, the company posted ($0.40) EPS. On average, analysts expect RenovoRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

RenovoRx Stock Performance

RenovoRx stock opened at $0.87 on Wednesday. The firm’s fifty day moving average price is $0.94 and its 200-day moving average price is $0.95. The stock has a market cap of $39.32 million, a P/E ratio of -2.73 and a beta of 1.00. RenovoRx has a fifty-two week low of $0.70 and a fifty-two week high of $1.45.

Analysts Set New Price Targets

Several analysts have recently weighed in on RNXT shares. JonesTrading upgraded shares of RenovoRx to a “strong-buy” rating in a research report on Thursday, January 29th. Ascendiant Capital Markets raised their price objective on shares of RenovoRx from $13.00 to $13.50 and gave the company a “buy” rating in a research report on Thursday, April 9th. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of RenovoRx in a research report on Wednesday, April 8th. Finally, Wall Street Zen cut shares of RenovoRx from a “hold” rating to a “strong sell” rating in a research report on Saturday, April 4th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, RenovoRx currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.25.

Hedge Funds Weigh In On RenovoRx

Several institutional investors and hedge funds have recently made changes to their positions in the business. XTX Topco Ltd grew its holdings in shares of RenovoRx by 58.6% during the 4th quarter. XTX Topco Ltd now owns 50,140 shares of the company’s stock valued at $42,000 after purchasing an additional 18,525 shares during the last quarter. Geode Capital Management LLC grew its holdings in RenovoRx by 9.9% in the 2nd quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock worth $467,000 after acquiring an additional 31,730 shares during the last quarter. Bleichroeder LP grew its holdings in RenovoRx by 11.4% in the 4th quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock worth $504,000 after acquiring an additional 61,379 shares during the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in RenovoRx in the 2nd quarter worth $98,000. Finally, Citadel Advisors LLC bought a new stake in RenovoRx in the 3rd quarter worth $154,000. Institutional investors own 3.10% of the company’s stock.

RenovoRx Company Profile

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.